Javascript must be enabled to continue!
Jujubes and Rosuvastatin: Comparison of Two Hypolipidemic Agents in Primary and Secondary Hyperlipidemic and Hypertensive Patients
View through CrossRef
Biotransformation in human body results accumulation of free radicals (reactive oxygen species or ROS). If patients LDL particles are more than normal in systemic circulation, get interacted with free radicals and form foamy cells; initial stage of coronary artery disease (CAD). Hyperlipidemia may be primary (genetic reason) or secondary which is acquired type of dyslipidemia. Free radicle formation in human body is very much normal phenomenon. Just reducing LDL or raising HDL may prevent interaction of LDL with reactive oxygen species (free radicals), escaping patient to develop CAD. Commonly used drugs in prophylaxis or treatment of dyslipidemia include statins (HMGCo-A reductase inhibitors), niacin, bile resins and fibric acids. There are alternative therapies for dyslipidemia including use of fibers, fruits, and vegetables. In Pakistan there are huge number of fruits and herbs which are getting popularity as hypolipidemic agents. One of the important fruit in Pakistan having hypolipidemic potential is JUJUBES (in urdu called Bair). In this study we have compared hypolipidemic effects of Bair with statin in hyperlipidemic patients. This study was conducted at Begum Jan hospital, Islamabad-Pakistan. Sixty hyperlipidemic patients were selected and divided in two groups. Their lipid profile (LP) was determined in the hospital and blood pressure (BP) was recorded at start of treatment. Group-1 was advised to take 10 mg tablet Rosuvastatin in divided doses, and group-2 was advised to use 500 mg Bair (JUJUBES) in divided times per day for the period of 2 months. RESULTS: after two months therapy their lipid profile and BP was re-determined and analyzed statistically by using SPSS version 22.00.01. It was observed that Rosuvastatin decreased systolic BP and LDL-c highly significantly (p-value < 0.001), while diastolic BP was reduced significantly (p-value <0.01) and HLD-c was increased significantly with p-value <0.01. In group-2 JUJUBES (Bair) reduced systolic BP and LDL-c significantly (p-value <0.01) but no significant changes were observed in diastolic BP and HDL-c in this group. CONCLUSION: It was concluded from the research study that Jujubes reduce LDL-c and systolic BP in hyperlipidemic patients, but lesser than statin group of antihyperlipidemic agents.
SASPR Edu International Pvt. Ltd
Title: Jujubes and Rosuvastatin: Comparison of Two Hypolipidemic Agents in Primary and Secondary Hyperlipidemic and Hypertensive Patients
Description:
Biotransformation in human body results accumulation of free radicals (reactive oxygen species or ROS).
If patients LDL particles are more than normal in systemic circulation, get interacted with free radicals and form foamy cells; initial stage of coronary artery disease (CAD).
Hyperlipidemia may be primary (genetic reason) or secondary which is acquired type of dyslipidemia.
Free radicle formation in human body is very much normal phenomenon.
Just reducing LDL or raising HDL may prevent interaction of LDL with reactive oxygen species (free radicals), escaping patient to develop CAD.
Commonly used drugs in prophylaxis or treatment of dyslipidemia include statins (HMGCo-A reductase inhibitors), niacin, bile resins and fibric acids.
There are alternative therapies for dyslipidemia including use of fibers, fruits, and vegetables.
In Pakistan there are huge number of fruits and herbs which are getting popularity as hypolipidemic agents.
One of the important fruit in Pakistan having hypolipidemic potential is JUJUBES (in urdu called Bair).
In this study we have compared hypolipidemic effects of Bair with statin in hyperlipidemic patients.
This study was conducted at Begum Jan hospital, Islamabad-Pakistan.
Sixty hyperlipidemic patients were selected and divided in two groups.
Their lipid profile (LP) was determined in the hospital and blood pressure (BP) was recorded at start of treatment.
Group-1 was advised to take 10 mg tablet Rosuvastatin in divided doses, and group-2 was advised to use 500 mg Bair (JUJUBES) in divided times per day for the period of 2 months.
RESULTS: after two months therapy their lipid profile and BP was re-determined and analyzed statistically by using SPSS version 22.
00.
01.
It was observed that Rosuvastatin decreased systolic BP and LDL-c highly significantly (p-value < 0.
001), while diastolic BP was reduced significantly (p-value <0.
01) and HLD-c was increased significantly with p-value <0.
01.
In group-2 JUJUBES (Bair) reduced systolic BP and LDL-c significantly (p-value <0.
01) but no significant changes were observed in diastolic BP and HDL-c in this group.
CONCLUSION: It was concluded from the research study that Jujubes reduce LDL-c and systolic BP in hyperlipidemic patients, but lesser than statin group of antihyperlipidemic agents.
Related Results
Cardiologists Do Advise Hyperlipidemic Patients to Maintain or Follow Prophylactic Measures in Scenario of Genetic Susceptibility of Hyperlipidemic Patients
Cardiologists Do Advise Hyperlipidemic Patients to Maintain or Follow Prophylactic Measures in Scenario of Genetic Susceptibility of Hyperlipidemic Patients
Biotransformation in human body results accumulation of free radicals (reactive oxygen species or ROS). If patients LDL particles are more than normal in systemic circulation, get ...
DETERMINATION OF PHYSICAL PROPERTIES AND CALIBRATION OF DISCRETE ELEMENT SIMULATION PARAMETERS FOR YIMENG MOUNTAIN JUJUBES
DETERMINATION OF PHYSICAL PROPERTIES AND CALIBRATION OF DISCRETE ELEMENT SIMULATION PARAMETERS FOR YIMENG MOUNTAIN JUJUBES
Accurate discrete element method (DEM) parameters are essential for simulating key operations in jujube postharvest processing, such as pneumatic cleaning during mechanical harvest...
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of highdensity lipoprotein (HDL) cholesterol. The ...
Metabolites of Rusuvastatin Inhibit Oxidation of both Low-Density Lipoproteins and Very Low-Density Lipoproteins
Metabolites of Rusuvastatin Inhibit Oxidation of both Low-Density Lipoproteins and Very Low-Density Lipoproteins
Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body. Plaque is ma...
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardi...
Is rosuvastatin protective against sepsis associated encephalopathy? A secondary analysis of the SAILS trial
Is rosuvastatin protective against sepsis associated encephalopathy? A secondary analysis of the SAILS trial
Abstract
Background
Sepsis is a common cause of death in emergency departments and sepsis associated encephalopathy is a major complication of sepsis. Rosuvastatin may hav...
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
Objectives
To explore the regulating lipid effects of Rosuvastatin on rats with dyslipidemia and its antiatherosclerotic effects.
...
Entanglement of AGE-RAGE axis in cardiac pathosis
Entanglement of AGE-RAGE axis in cardiac pathosis
Abstract
Cardiovascular diseases are the major cause of death globally. Acute coronary syndrome is one of numerous cardiovascular illnesses, including advanced glyc...

